Novo Nordisk’s Russian Profit Surprise Masks a Growing Legal Headache
Novo Nordisk investors are digesting a curious paradox: the Danish drugmaker’s Russian subsidiary has more than quadrupled its…
Novo Nordisk’s Buyback Blitz Masks Building Pressure Ahead of 2027 Price Cuts
The Danish pharmaceutical heavyweight is buying back shares at a record pace, yet the same weekly disclosures that…
Novo Nordisk’s 20% Rally Masks a Fundamental Gap and an FDA Clock That Hasn’t Run Out
Novo Nordisk has clawed back nearly a fifth of its value in the past month, closing Friday at…
Novo Nordisk’s One-Time Windfall Masks a Deeper Squeeze as Pipeline Bets Take Shape
Novo Nordisk’s Q1 profit surged on a one-off accounting gain, but US sales fell 11% amid pricing pressure.…
Novo Nordisk’s Profit Surge Masks the Real Story: A Pipeline Pivot Underway
Novo Nordisk beats Q1 earnings estimates, scraps CagriSema combo therapy, raises 2026 guidance, and bets on oral GLP-1…